Immuneering Corporation (BOATS:IMRX) Financings

Immuneering Corporation

Financings

RaiseDate
Public offering of class A common stock or pre-funded warrants
Announced: Leerink Partners +1
Dealers: Leerink Partners (co-lead), Oppenheimer & Co. Inc. (co-lead)
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Sep 24, 2025
Private placement of class A common stock or non-voting Class B common stock
Announced: US$25M · Leerink Partners +1
Dealers: Leerink Partners, Oppenheimer & Co. Inc.
Buyers: Sanofi ($25.0 million of Class A common stock or non-voting Class B common stock)
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Sep 24, 2025
Private placement of class A common stock (or pre-funded warrants) and accompanying purchase warrants
Closed: US$25M raised · US$3.95 a share · Warrants at US$5.5 for 60 months · Leerink Partners
Dealers: Leerink Partners
Use of proceeds: Support development of atebimetinib, its Deep Cyclic Inhibitor of MEK, for cancer patients
Aug 26, 2025
At-the-market programme of common stock
Closed: US$13.7M raised
Jan 13, 2025

Read by 6ix AI from the company's releases